Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Assertio Holdings, the most common co-covered peer. Perspective Therapeutics appears in 1 tracked Biotech story from March 13, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Assertio Holdings, the most common co-covered peer. Perspective Therapeutics appears in 1 tracked Biotech story from March 13, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Perspective Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Perspective Therapeutics and Assertio Holdings are preparing to report Q4 2025 results, with investors focused on Perspective's radiopharmaceutical pipeline and Assertio's commercial execution of its expanded portfolio. These reports will provide critical updates on clinical milestones and revenue diversification strategies for both specialty players.
Perspective Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
